Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7052W HIGH $8.33
Volume
2.49 M
Value Traded
6.54 M
Short % Float
7.9%
-15.9%Week
-10.58%1 Month
-14.76%3 Month
-18.21%6 Month
-77.53%5 Year
-72.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
568.06 M
EPS (TTM)
-0.52
P/E Ratio
-
Ent. Value
358.75 M
Total Shares
100.36 M
Float Shares
86.22 M
Insiders
14.10%
Institutions
71.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
STTK Catalyst Timeline
Dated clinical, regulatory and corporate events for Shattuck Labs, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Shattuck Labs, Inc.
288Total events
8Upcoming
31Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
◆Trial InitiationSL-325Trial
Phase 2 trial in Crohn's disease expected to initiate
Crohn's diseasesource ↗
▼Equity OfferingCorporate
Pricing of $75 million public offering of common stock and pre-funded warrants
▲Equity OfferingCorporate
Exercise of approximately 50.6 million common stock warrants for aggregate gross proceeds of approximately $54.9 million
▲Runway Guidance UpdateCorporate
Cash runway guidance extended into 2029 based on current operational plans and warrant proceeds
◆Oral PresentationSL-325Presentation
Investor call and webcast presenting Phase 1 clinical data for SL-325
inflammatory and immune-mediated diseasessource ↗
▲Enrollment CompleteSL-325Trial
Phase 1 trial of SL-325 enrollment complete
healthy volunteerssource ↗
●IND Enabling CompletePreclinical
Lead bispecific antibody enters IND-enabling activities
inflammatory and immune-mediated diseasessource ↗
◆Enrollment CompleteSL-325Trial
Phase 1 enrollment completion expected
inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseasessource ↗
●Trial CompletionSL-325Trial
Phase 1 trial expected to complete
inflammatory and immune-mediated diseasessource ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Health Care Conference one-on-one meetings
▲Enrollment CompleteSL-325Trial
Enrollment of all six SAD cohorts completed
healthy volunteerssource ↗
●IND Enabling CompletePreclinical
Lead bispecific antibody entered IND-enabling activities
inflammatory and immune-mediated diseasessource ↗
◆Oral PresentationPresentation
TD Cowen 46th Annual Health Care Conference corporate presentation
◆Oral PresentationPresentation
Shattuck Labs management to participate in fireside chat at Piper Sandler Virtual Novel Targets in Immunology Symposium
▲First Patient DosedSL-325Trial
First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers
inflammatory and immune-mediated diseasessource ↗
◆Management ChangeCorporate
Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors
◆Runway Guidance UpdateCorporate
Cash runway guidance: funds expected into 2029 assuming full exercise of warrants
●Trial InitiationSL-325Trial
MAD portion of Phase 1 trial expected to commence
inflammatory and immune-mediated diseasessource ↗
●Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference presentation
●IND SubmissionSL-325IND
IND submission for SL-325
Inflammatory Bowel Disease (IBD) and other autoimmune diseasessource ↗
◆Oral PresentationPresentation
DR3/TL1A focused panel discussion at Leerink Partners Therapeutics Forum
◆First Patient DosedSL-325Trial
First patient in for SAD portion of Phase 1 trial expected
inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseasessource ↗
●IND SubmissionSL-325IND
IND submitted to FDA for SL-325
inflammatory and immune-mediated diseasessource ↗
◆Trial InitiationSL-325Trial
Phase 1 trial initiation in healthy volunteers
healthy volunteerssource ↗
▲IND ClearanceSL-325IND
IND clearance for SL-325 expected
Inflammatory Bowel Disease (IBD) and other autoimmune diseasessource ↗
◆Oral PresentationPresentation
Shattuck Labs management to present at 24th Annual Needham Virtual Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How STTK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | SL-325 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$228M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.4x
rNPV / MCap
Top 43%
Micro Cap(rank 284 of 658)
Percentile Rank
Shattuck Labs, Inc. faces pipeline headwinds (39/100), with $570M risk-adjusted pipeline value, led by SL-325 in Crohn's Disease (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SL-325 Small moleculeNCT07753850 | Crohn's Disease | Phase 2 | NOT YET_RECRUITING | 232 | Jun 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every STTK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SL-325 | inflammatory diseases | Phase 1 | 2026-06-08 | 3.7% of participants developing antidrug antibodies; Complete blockade of TL1A binding for over 3 months; 72 participants enrolled; Doses ranging from 0.1 mg/kg to 30.0 mg/kg; Complete DR3 occupancy observed at doses of 0.1 mg/kg and higher; Durable inhibition of TL1A binding for more than 10 weeks; Accumulation ratio of 1.64-1.75Read More | Shattuck Labs Announces Phase 1 Results for SL-325Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shukla Abhinav A.Officer (Chief Technical Officer) | Option | 12,153 98,533 held | $3.57 | 07/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STTK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 3.2 % (33.3 %) | 47.83 M | 6.89 M | 24.41% ( 1.35 M) |
STTK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STTK ranks across every disease it competes in
Competitive Position is a premium feature
See how STTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTTK News
STTKShattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Shattuck Labs announced the initiation of the RECEPTIVE-HS1 Phase 2 clinical trial for SL-325, targeting moderate to severe hidradenitis suppurativa (HS), expected to start in 2026. The trial will evaluate the efficacy and safety of SL-325 compared to placebo, with results anticipated in early 2028. Dr. Shoba Ravichandran has been appointed as Senior Vice President of Clinical Development to lead this program.
Read more →STTKShattuck Labs Announces Participation in Upcoming September Investor Conferences
Shattuck Labs, Inc. has announced its participation in two upcoming investor conferences, the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. CEO Taylor Schreiber and CFO Andrew Neill will present at both events, providing insights into the company's pioneering work in monoclonal and bispecific DR3 blocking antibodies. Live audio webcasts will be available for interested parties.
Read more →STTKShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs reported its Q2 2026 financial results, highlighting positive Phase 1 trial outcomes for SL-325, a promising treatment for Crohn's disease. The company plans to initiate a Phase 2b trial in the third quarter of 2026. Additionally, Shattuck's financial health remains strong, with significant cash reserves to support ongoing operations.
Read more →STTKShattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs, Inc. has announced the pricing of a public offering of approximately $75 million, consisting of 10,879,376 shares at $4.00 each and pre-funded warrants. The offering is expected to close on June 11, 2026, pending customary conditions. Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor are the joint bookrunning managers for this offering.
Read more →STTK▲ +9.5%on this news· ran to +27% by day 3shared move
Shattuck Labs, Inc. Announces Proposed Public Offering
Shattuck Labs, Inc. has announced a proposed public offering of its common stock, with the option for certain investors to purchase pre-funded warrants. The offering is subject to market conditions, and the company has engaged several prominent underwriters. Shattuck Labs specializes in developing innovative therapies for inflammatory and immune-mediated diseases.
Read more →STTK▲ +9.5%on this news· ran to +27% by day 3shared move
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Shattuck Labs has announced the exercise of approximately 50.6 million common stock warrants, resulting in expected gross proceeds of about $54.9 million. This follows the exercise of over 5 million warrants earlier this year. The company reports having sufficient cash reserves to support its operations until 2029, based on current plans.
Read more →STTK▼ -14.8%on this newsshared move
Shattuck Labs Announces Phase 1 Results for SL-325
Shattuck Labs announced positive Phase 1 results for SL-325, its lead DR3 blocking antibody. The trial demonstrated a favorable safety profile and a potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies. SL-325 achieved complete blockade of TL1A binding for over three months, supporting its efficacy for treating inflammatory diseases. A Phase 2b trial in Crohn's disease is expected to begin in Q3 2026.
Read more →STTKShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs will host an investor call on June 8, 2026, to discuss Phase 1 clinical data for SL-325, a DR3 blocking antibody. The presentation will cover safety, pharmacokinetics, and immunogenicity results, along with a pipeline update. Key executives will present and participate in a Q&A session.
Read more →STTK▼ -6.3%on this news
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs has completed enrollment in its Phase 1 clinical trial of SL-325, with data expected in the second quarter of 2026. The company plans to initiate a Phase 2 trial for Crohn's disease in the third quarter of 2026, contingent on positive Phase 1 results. Financially, Shattuck reported a net loss of $14.8 million for the first quarter of 2026, while maintaining a strong cash position.
Read more →STTK▲ +7.8%on this news· ran to +27% by day 1
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported its financial results for Q4 and full year 2025, highlighting the ongoing Phase 1 trial of SL-325, with data expected in Q2 2026. The company anticipates initiating a Phase 2 trial for Crohn's disease in Q3 2026. Despite a net loss of $12.6 million for Q4, recent capital raises have improved their financial standing.
Read more →STTK▼ -5.4%on this news
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
Shattuck Labs, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. CEO Taylor Schreiber will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, and engage in one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference on March 10-11, 2026. The company is focused on developing first-in-class DR3-blocking antibodies for inflammatory diseases.
Read more →STTK▲ +5.6%on this news
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
Shattuck Labs, Inc. announced its participation in the Piper Sandler Virtual Novel Targets in Immunology Symposium scheduled for February 12-13, 2026. The company's management will engage in a fireside chat, featuring key executives discussing their innovative therapies. Notably, Shattuck is advancing SL-325, a potential first-in-class antibody targeting the DR3/TL1A pathway, currently in Phase 1 trials.
Read more →STTKShattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Shattuck Labs, Inc. announced the granting of inducement equity awards to a newly-hired non-executive officer, consisting of non-qualified stock options for 206,000 shares at an exercise price of $3.23. These options will vest over a period of time, starting in November 2026. This move aligns with Nasdaq Listing Rule 5635(c)(4) and highlights the company's ongoing commitment to attract talent.
Read more →STTKShattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs, Inc. announced its participation in several investor conferences in December 2025, including the Piper Sandler 37th Annual Healthcare Conference and the Evercore ISI 8th Annual HealthCONx Conference. CEO Taylor Schreiber will present at both events, discussing the company's innovative therapies targeting TNF superfamily receptors. The company is advancing its lead program, SL-325, currently in Phase 1 trials.
Read more →STTKShattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported its third quarter 2025 financial results, highlighting the initiation of a Phase 1 clinical trial for SL-325, a novel DR3 blocking antibody. The company successfully closed a $103 million private placement to support further development. CEO Taylor Schreiber expressed confidence in advancing SL-325 into Phase 2 trials, backed by a strong cash position.
Read more →STTKShattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
Shattuck Labs, Inc. will participate in the Wedbush Securities KOL panel discussing insights from the UEGW Conference 2025. The session features key opinion leader Marla Dubinsky and will be moderated by analysts Martin Fan and David Nierengarten. Shattuck's CEO, Taylor Schreiber, will represent the company during this event.
Read more →STTKShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Shattuck Labs has successfully closed a private placement of up to $103 million, which will fund its SL-325 program through multiple Phase 2 clinical trials, including studies in Inflammatory Bowel Disease. The company has appointed two new board members, enhancing its leadership with experienced industry professionals. This financing positions Shattuck to advance its innovative therapies into 2029.
Read more →STTK▼ -11.9%on this newsshared move
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Shattuck Labs has announced that its IND application for SL-325, a DR3 antagonist antibody for inflammatory bowel disease, is now effective. The company plans to begin dosing the first participant in its Phase 1 clinical trial in Q3 2025, with enrollment expected to complete by Q2 2026. The trial will evaluate the safety and pharmacokinetics of SL-325 in healthy volunteers.
Read more →STTK▲ +6.1%on this news· ran to +27% by day 3
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported its second quarter 2025 financial results, highlighting the submission of an IND application for the SL-325 drug candidate, expected to clear in Q3 2025. The company has adequate funds, estimated at $50.5 million, to support operations into 2029 after a successful private placement. The Phase 1 clinical trial for SL-325 is set to begin enrollment in Q3 2025. However, the company experienced a net loss of $12.5 million for the quarter and a decrease in cash reserves compared to the previous year.
Read more →STTK▲ +33.3%on this news
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
Shattuck Labs announced a successful private placement financing expected to yield approximately $103 million. The funds will support the development of SL-325 through multiple Phase 2 clinical trials targeting inflammatory bowel disease and other autoimmune conditions. The company anticipates that the proceeds will sustain operations into 2029, contingent on regulatory approvals.
Read more →About Shattuck Labs, Inc.
Headquarters500 W. 5TH STREET, AUSTIN, TX, 78701
BIOPHARMAWATCH ELITE PLUS
Trade the next STTK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime